Free Trial
NASDAQ:IRWD

Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis

Ironwood Pharmaceuticals logo
$1.61 +0.15 (+10.27%)
Closing price 10/2/2025 04:00 PM Eastern
Extended Trading
$1.64 +0.03 (+1.80%)
As of 08:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD)

Advanced

Key Stats

Today's Range
$1.45
$1.61
50-Day Range
$0.75
$1.61
52-Week Range
$0.53
$5.13
Volume
754,517 shs
Average Volume
1.38 million shs
Market Capitalization
$261.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.94
Consensus Rating
Hold

Company Overview

Ironwood Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

IRWD MarketRank™: 

Ironwood Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 203rd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ironwood Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.

  • Upside Potential

    Ironwood Pharmaceuticals has a consensus price target of $4.94, representing about 206.8% upside from its current price of $1.61.

  • Amount of Analyst Coverage

    Ironwood Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Ironwood Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Ironwood Pharmaceuticals are expected to grow by 150.00% in the coming year, from $0.10 to $0.25 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ironwood Pharmaceuticals is -32.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ironwood Pharmaceuticals is -32.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Ironwood Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    3.65% of the float of Ironwood Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ironwood Pharmaceuticals has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Ironwood Pharmaceuticals has recently decreased by 5.78%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Ironwood Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Ironwood Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.65% of the float of Ironwood Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ironwood Pharmaceuticals has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Ironwood Pharmaceuticals has recently decreased by 5.78%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Ironwood Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    6 people have searched for IRWD on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ironwood Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.70% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Ironwood Pharmaceuticals' insider trading history.
Receive IRWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IRWD Stock News Headlines

Ironwood Pharma Regains Nasdaq Compliance
Ironwood (IRWD) Q2 EPS Jumps 600%
A Huge Shift Is Underway in America
Wall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who predicted the 2008 crash and 2020 says today's soaring markets are NOT a bubble - they're something far stranger and more dangerous. He says it's about to change everything you know about money.tc pixel
See More Headlines

IRWD Stock Analysis - Frequently Asked Questions

Ironwood Pharmaceuticals' stock was trading at $4.43 at the start of the year. Since then, IRWD stock has decreased by 63.7% and is now trading at $1.61.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings data on Thursday, August, 7th. The biotechnology company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.16. The biotechnology company earned $85.24 million during the quarter, compared to analyst estimates of $62.02 million. Ironwood Pharmaceuticals had a negative trailing twelve-month return on equity of 2.46% and a negative net margin of 2.25%.

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
8/07/2025
Today
10/02/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IRWD
CIK
1446847
Employees
220
Year Founded
N/A

Price Target and Rating

High Price Target
$14.00
Low Price Target
$0.70
Potential Upside/Downside
+206.8%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
16.10
P/E Growth
N/A
Net Income
$880 thousand
Net Margins
-2.25%
Pretax Margin
13.91%
Return on Equity
-2.46%
Return on Assets
2.19%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.82
Quick Ratio
0.82

Sales & Book Value

Annual Sales
$351.41 million
Price / Sales
0.74
Cash Flow
$0.05 per share
Price / Cash Flow
29.52
Book Value
($1.88) per share
Price / Book
-0.86

Miscellaneous

Outstanding Shares
162,430,000
Free Float
141,805,000
Market Cap
$261.51 million
Optionable
Optionable
Beta
0.30

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:IRWD) was last updated on 10/3/2025 by MarketBeat.com Staff
From Our Partners